Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Altuviiio Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Kit—1 (single-dose vial + diluent, adapter)
Manufacturer
Generic Availability
NO
Mechanism of Action
Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. Appending the D’D3 domain of VWF to a recombinant FVIII-Fc fusion protein provides protection and stability to FVIII, and prevents FVIII interaction with endogenous VWF, thus overcoming the limitation on FVIII half-life imposed by VWF clearance. The 2 XTEN polypeptides alter the hydrodynamic radius of the fusion protein, thus reducing rates of clearance and degradation, and improving pharmacokinetic properties.
Altuviiio Indications
Indications
In patients with Hemophilia A: for on-demand treatment and control of bleeding episodes, for perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.
Limitations of Use
Not for von Willebrand disease.
Altuviiio Dosage and Administration
Adults and Children
Dosage Required (IU) = Body Weight (kg) x Desired Factor VIII Increase (IU/dL or % normal) x 0.5 (IU/kg per IU/dL). Individualize. Give as IV inj at max rate of 6mins/vial (<20kg); 2–3mins/vial (≥20kg); 1–2mins/vial (adults and adolescents). Routine prophylaxis: 50 IU/kg once weekly. On-demand (Minor and moderate): 50 IU/kg once; use 30 IU/kg if bleeding episode occurs within 2–3 days after prophylactic dose; may consider additional doses of 30 or 50 IU/kg every 2–3 days; (Major): 50 IU/kg once; may consider additional doses of 30 or 50 IU/kg every 2–3 days. May resume prophylaxis after ≥72 hours interval. Perioperative (Minor): 50 IU/kg once; may consider additional doses of 30 or 50 IU/kg after 2–3 days; (Major): 50 IU/kg once; may give additional doses of 30 or 50 IU/kg every 2–3 days, as clinically needed.
Altuviiio Contraindications
Not Applicable
Altuviiio Boxed Warnings
Not Applicable
Altuviiio Warnings/Precautions
Warnings/Precautions
Discontinue if hypersensitivity reactions (eg, anaphylaxis) occur. Neutralizing antibodies formation. Monitor for development of FVIII inhibitors. If bleeding uncontrolled and FVIII activity plasma levels not attained, perform assay to determine presence of FVIII inhibitors. Pregnancy. Nursing mothers.
Altuviiio Pharmacokinetics
Elimination
Half-life: 48.2 hours (adults), 44.6 hours (12–<18 years), 42.4 hours (6–<12 years), 39.9 hours (1–<6 years).
Altuviiio Interactions
Not Applicable
Altuviiio Adverse Reactions
Adverse Reactions
Headache, arthralgia; hypersensitivity reactions.
Altuviiio Clinical Trials
See Literature
Altuviiio Note
Not Applicable
Altuviiio Patient Counseling
See Literature
